SXTP Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

60 Degrees Pharmaceuticals Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerSXTP

Market Cap3.9M

Cash RunwayRunway < 6 months

Next Catalyst2026-12-08

Public Research Snapshot

60 Degrees Pharmaceuticals Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for CELGOSIVIR (Approved).

Pipeline

Asset	Indication	Modality	Stage	Public Note
CELGOSIVIR	n/a	n/a	Approved	Public pipeline row
mRNA-1645-eODGT8	HIV Infections	Mrna	Phase 1	Public pipeline row
Photodynamic Therapy	Non Small Cell Lung Cancer	n/a	Na	Public pipeline row
NPX372	Metastatic Malignant Neoplasm	n/a	Phase 1	Public pipeline row
PF-06700841	Psoriasis	n/a	Phase 2	Public pipeline row
Whole-Body Electrical Muscle Stimulation (WB-EMS) Training	Athletic Performance \| Plyometric Exercise \| Healthy	n/a	Na	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2026-12-08	mRNA-1645-eODGT8	Low
Clinical Trial Completion	2026-12-31	Whole-Body Electrical Muscle Stimulation (WB-EMS) Training	Low
Clinical Trial Completion	2027-04-01	NPX372	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03564054	Na	TERMINATED	3	2019-09-30
NCT03850483	Phase 2	COMPLETED	344	2021-04-20
NCT06694753	Phase 1	RECRUITING	96	2026-12-08
NCT06546605	Na	RECRUITING	120	2026-12-31
NCT07563829	Phase 1	NOT_YET_RECRUITING	81	2027-04-01

Scientific Context

literature_publication | Acute kidney injury and chronic kidney disease in the aging critically ill patient.
literature_publication | VISIION-L: Viz.ai implementation of stroke augmented intelligence and communications platform to improve indicators and outcomes for a comprehensive stroke center and network - Life Flight. A pilot experience.
literature_publication | Effect of autologous platelet-rich plasma on optical quality and visual outcomes following implantation of a trifocal diffractive intraocular lens.
literature_publication | SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.
literature_publication | Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907).

Want the full SXTP research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.